Trial NCT05711628

View at ClinicalTrials.gov 
Org. Study IDs: NCI-2023-00575
Secondary IDs: EA4211 NCI-2023-00575 U10CA180820

Last trial update was posted on 2024-03-20

MeSH Interventions

Antibodies Antibodies, Monoclonal Antineoplastic Agents, Immunological Bendamustine Hydrochloride Brentuximab Vedotin Carboplatin Doxorubicin Etoposide Etoposide phosphate Gemcitabine Ifosfamide Immunoconjugates Immunoglobulins Isophosphamide mustard Liposomal doxorubicin Pembrolizumab Podophyllotoxin Vinorelbine

MeSH Conditions

Hodgkin Disease Lymphoma

Other Conditions

Recurrent Classic Hodgkin Lymphoma Refractory Classic Hodgkin Lymphoma

Stopping Reasons

Other - Protocol moved to Withdrawn

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID